Member Info for DugWalker

My understanding is that the NSC recommendation not to have a national screening programme is based on current testing methods which rely heavily on PSA testing. The recommendation could change once the results of the Transform project are available. Of course OBD chose not to participate in Transformin spite of a previous C.E.O. stating that OBD participation was critical. The company has been treading water for several years now and there are no indications that this is about to change.

The SP here is not likely to grow substantially until they get drilling in Spain or Italy. A reasonable hike could follow publication of the seismics from Italy particularly if accompanied by detailed drilling plans and timelines.

Is 'this' viable?

Depends on what 'this' is. If 'this' refers to the licence and the intent to explore for gas then the answer is yes, but with other wells to be drilled in Italy and Spain it cannot be a priority until these new income streams are established.

If 'this' is a shallow (600m) oil well producing circa 50 bbl per day then the answer is it could be. A well generating £1 million per annum using simple extraction technology (nodding donkey) is marginal to moderate. The cost to drill and install would be circa £0.5 to £1 million. Much would depend on the commercials related to processing and selling price. Think of it as a potential cherry on the cake. The cake is the discovery of a meaningful gas field.

Geography doesn't change the fundamental that Medics will always be hesitant about recommending a test to patients if said test has not been clinically validated. In the US a doctor that recommends a treatment strategy for cancer based on the result of such a test is inviting litigation should anything go remotely wrong.

The reason nobody buys their products is that they are only validated as lab tests. Not one of their products has undergone the sort of large scale clinical trials needed to satisfy regulators and the wider medical community.

What it has brought is another national news item promoting rapid MRI scans as a basis for a screening programme.

It is shameful that OBD has continually failed to pursue participation in the Prostate Cancer "Transform" project. This could have financed proper medical validation of PSE. There is a world of difference between medical validation and validation of a laboratory test which is what this lot refer to whenever they claim their tests are validated. Can only assume the strategy has been to await a takeover by "big Pharma" to finance the validation at scale needed to convince medical regulators and practitioners, but why would big Pharma not just await the inevitable administration of OBD and pick up the IP for pennies?

What question marks?

Volume is low so far but the price has ticked up accordingly. One of very few share prices to go up today.

Last time gas price was this high my memory is that share price would have been mid to high teens.

Wow.

At this stage of their development its still very much a case of speculate to accumulate. R&D and business ess development costs are likely to be disproportionately high.

A bounce anticipated in the US would drive TTF upwards. Good news considering Selve is profitable down into the teens.

Natural Gas Price Outlook – Natural Gas Continues to Drop | FXEmpire https://share.google/9aSjgZY78G3UXpZYx

‘Dark Fleet’ LNG Carrier Forced to Turn Back as Early Winter Ice Blocks Access to Arctic LNG 2 https://share.google/mhmLryahkUV5pOyGY

I have already stated what my eyes tell me. Low volume trading, few investors and impatience. It'll drift along at these levels until there is meaningful news that increases revenues or resources. The publically available data simply doesn't support claims of regular 'large rounded sales'.

If the 3D seismics from Selva due end Q1 /start Q2 result in a significant increase in resources that could catalyse a strong recovery. Assets will win out here, it's just a matter of time.

If as implied there was a constant selling of 'big rounded numbers' I'd expect to see TR1 announcements. I'm not. In reality I'm seeing low volume trading and a SP drifting lower because of that. It will rapidly recover as soon as there is some buying. There isnt much at the moment because drilling schedules have been pushed back towards the turn of next year.

A response that starts with 'Yawn' doesnt convince that you're arguments or posts are well considered.

I'm fully aware of what has been said in RNS's and in interviews. I note that you have circumvented my remark that a debt facility could be easily secured (and most probably will be in response to pressure from TR1 shareholders who will not want to see further dilution ). Routh is well aware that the recent placings were not well received and self preservation will now be high on his agenda. That means prioritising alternative sources of funding if required. It won"t be hard to come by you seem strangely unwilling to acknowledge that.

As for the SP it has been declining because genuine investors are a minority in AIM companies and the traders are too impatient to see out the impact of z transformational 18 months ahead.

Routh has said drills will be funded organically or via farm outs or finance if necessary. Not remotely sure why SneakySimon thinks banks would refuse PXEN a loan of up to £8 million when it could easily be secured against the Viura repayments that include 10% interest payments! The reason he has not ruled out future raises is he cant predict the future which means it'd be irresponsible to do so. What if a shareholder accretive merger or acquisition suddenly arose, for example, and banks didn't want to increase an existing debt facility? Would we just walk away even if we thought the transaction was transformative?

Still no demonstrable ability to pay the wages let alone cover overheads. Yet another.placing won't be far off.

Sept 27 brings pressure to find alternative sources in the interim.

No direct impact. What about the indirect impact? How about exploiting the 300000 blood samples being collected by Transform to validate the test?

When starting from sales numbers you can count on your fingers and toes it's deliberate obfuscation to be shouting about 6 months of 'record sales" with no quantification. Just shut up until you are selling enough to the ⁶to pay the wages.

Encouraging progress on the Selva 3D seismic from Po Valley. Data collection well advanced and to be completed this month. Data analysis finalised by April 26.

ASX:PVE - Update on Selva Malvezzi Concession Activities https://share.google/rMqTxQiFi5cZrrCGx